Fan Fan, Feng Ruiwen, Zhang Yuxin, Li Xiabin, Tang Yan
School of Public Health, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Chongqing Key Laboratory of Biomedical Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing, 400016, People's Republic of China.
Clin Transl Oncol. 2025 Apr;27(4):1569-1585. doi: 10.1007/s12094-024-03714-y. Epub 2024 Sep 12.
Globally, breast cancer is the most common type of malignant tumor. It has been demonstrated that TMEM41A is abnormally expressed in a number of cancers and is linked to a dismal prognosis. TMEM41A's involvement in breast cancer remains unknown, though.
Data from databases such as TCGA were used in this study. Expression differences were compared using non-parametric tests. Cox regression analysis was employed, and analyses such as Nomogram were used to assess the significance of TMEM41A in predicting the prognosis of breast cancer. Lastly, it was looked into how immune cell infiltration in breast cancer is related to TMEM41A expression levels.
The results suggest that TMEM41A is overexpressed in breast cancer and correlates with poor prognosis (P = 0.01), particularly in early-stage and ductal A breast cancer (P < 0.01). Breast cancer patients' expression of TMEM41A was found to be an independent risk factor (HR = 1.132, 95% CI 1.036-1.237) by multifactorial Cox regression analysis. The Nomogram prediction model's c-index was 0.736 (95% CI 0.684-0.787). The results of GSEA biofunctional enrichment analysis included the B cell receptor signaling pathway (P < 0.05). Ultimately, there was a significant correlation (P < 0.05) between TMEM41A expression in breast cancer and an infiltration of twenty immune cells.
Breast cancer tissues overexpress TMEM41A, which is linked to immune cell infiltration and prognosis (particularly in early stage and luminal A breast cancer). Overexpression of TMEM41A is anticipated to serve as a novel prognostic indicator and therapeutic target for breast cancer.
在全球范围内，乳腺癌是最常见的恶性肿瘤类型。已有研究表明，跨膜蛋白41A（TMEM41A）在多种癌症中异常表达，并与预后不良相关。然而，TMEM41A在乳腺癌中的作用尚不清楚。
本研究使用了来自TCGA等数据库的数据。采用非参数检验比较表达差异。进行Cox回归分析，并使用列线图等分析方法评估TMEM41A在预测乳腺癌预后中的意义。最后，研究了乳腺癌中免疫细胞浸润与TMEM41A表达水平的关系。
结果表明，TMEM41A在乳腺癌中高表达，与预后不良相关（P = 0.01），尤其是在早期和乳腺导管A型癌中（P < 0.01）。多因素Cox回归分析发现，乳腺癌患者TMEM41A的表达是一个独立危险因素（HR = 1.132，95%CI 1.036 - 1.237）。列线图预测模型的c指数为0.736（95%CI 0.684 - 0.787）。基因集富集分析（GSEA）的生物功能富集分析结果包括B细胞受体信号通路（P < 0.05）。最终，乳腺癌中TMEM41A的表达与20种免疫细胞的浸润之间存在显著相关性（P < 0.05）。
乳腺癌组织中TMEM41A高表达，这与免疫细胞浸润和预后相关（尤其是在早期和乳腺导管A型癌中）。预计TMEM41A的高表达将成为乳腺癌的一种新的预后指标和治疗靶点。
